| | | | | 2 | | | |
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | ||||
| | |||||||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| ||||||||
| | | |
| | |||||||
| ||||||||
| | | | | | |||
| | | | | | | ||
| | | | | ||||
| | |||||||
| | | | | | | ||
| | | | | 35 | | | |
| | | | | 40 | | | |
| | | | | 40 | | | |
| | | | | 40 | | | |
| | | | | 40 | | | |
| | | | | 40 | | | |
| | | | | | | ||
| | | | | | | ||
| | | | | ||||
| | |||||||
| | | | | | | ||
| | | | | | | ||
| | | | | ||||
| |
| | | | | ||||
| | |||||||
| | | | | ||||
| | |||||||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | ||||
| | |||||||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| ||||||||
| | | | | |
Board Diversity Matrix | | ||||||||||||||||||||||||
Board Size: | | | | | | | | | | | | | | | | | | | | | | | | | |
Total Number of Directors: 7 | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | Female | | | Male | | | Non-Binary | | | Did Not Disclose Gender | | ||||||||||||
Part I: Gender Identity | | | | | | | | | | | | | | | | | | | | | | | | | |
Directors | | | | | 1 | | | | | | 6 | | | | | | | | | | | | | | |
Part II: Demographic Background* | | | | | | | | | | | | | | | | | | | | | | | | | |
African American | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Alaskan Native or American Indian | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Asian | | | | | 0 | | | | | | 1 | | | | | | 0 | | | | | | 0 | | |
Hispanic or Latinx | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Native Hawaiian | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
White | | | | | 1 | | | | | | 5 | | | | | | 0 | | | | | | 0 | | |
Two or More Races or Ethnicities | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
LGBTQ+ | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Did not Disclose Demographic Background | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | Female | | | Male | | | Non-Binary | | | Did Not Disclose Gender | | ||||||||||||
Part I: Gender Identity | | | | | | | | | | | | | | | | | | | | | | | | | |
Directors | | | | | 1 | | | | | | 6 | | | | | | | | | | | | | | |
Part II: Demographic Background* | | | | | | | | | | | | | | | | | | | | | | | | | |
African American | | | | | 0 | | | | | | 1 | | | | | | 0 | | | | | | 0 | | |
Alaskan Native or American Indian | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Asian | | | | | 0 | | | | | | 1 | | | | | | 0 | | | | | | 0 | | |
Hispanic or Latinx | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Native Hawaiian | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
White | | | | | 1 | | | | | | 4 | | | | | | 0 | | | | | | 0 | | |
Two or More Races or Ethnicities | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
LGBTQ+ | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Did not Disclose Demographic Background | | | | | | | | | | | | | | | | | | | | | | | | | |
Name | | | Age | | | Present Position with Nutex Health Inc. | |
Thomas T. Vo, M.D., MBA | | | | | Chief Executive Officer and Chairman of the Board | | |
Warren Hosseinion M.D. | | | | | President and Director | | |
Mitchell Creem, MHA | | | | | Independent Director | | |
Cheryl Grenas, R.N., M.S.N | | | | | Independent Director | | |
Michael L. Reed, MPH | | | | | Independent Director | | |
| | | | Director | | ||
Scott J. Saunders, MPPM | | | 61 | | | Independent | |
Director | |
Name | | | Audit Committee | | | Compensation Committee | | | Nominating and Corporate Governance Committee | | |||||||||
Thomas T. Vo, M.D., MBA | | | | | | | | | | | | | | | | | | | |
Warren Hosseinion, M.D. | | | | | | | | | | | | | | | | | | | |
Mitchell Creem, MHA | | | | | | | | | | X | | | | | | X | | | |
Cheryl Grenas, R.N., M.S.N | | | | | | | | | | | | | | | | X | | | |
Michael L. Reed, MPH | | | | | X | | | | | | X | | | | | | | | |
| | | | X | | | | | | | | | | | | | |||
| | | | | | | | | | | | | | | | | | |
| Additional Annual Retainer for Committee Membership | | | | | | | Additional Annual Retainer for Committee Membership: | | | | | | | ||
| Audit Committee Chairman | | | $ | 20,000 | | | Audit Committee Chairman | | | $ | 20,000 | | | ||
| Compensation Committee Chairman | | | $ | 15,000 | | | Compensation Committee Chairman | | | $ | 15,000 | | | ||
| Nominating and Governance Committee Chairman | | | $ | 15,000 | | | Nominating and Governance Committee Chairman | | | $ | 15,000 | | |
| John Waters, Audit Committee Chair | | | | $ | 148,748 | | |
| Mitchell Creem, Compensation Committee Chair | | | | $ | 144,375 | | |
| Michael Reed, Nominating and Governance Audit Committee Chair | | | | $ | 144,375 | | |
| Cheryl Grenas, Director | | | | $ | 131,250 | | |
| John Waters, Audit Committee Chair | | | | $ | 148,743 | | |
| Mitchell Creem, Compensation Committee Chair | | | | $ | 144,375 | | |
| Michael Reed, Nominating and Governance Audit Committee Chair | | | | $ | 144,375 | | |
| Cheryl Grenas, Director | | | | $ | 131,250 | | |
Name | | Fees Earned or Paid in Cash ($) | | Stock Awards ($)(1) | | Total ($) | | | Fees Earned or Paid in Cash ($) | | Stock Awards ($)(1) | | Total ($) | | ||||||||||||||||||||||||
John Waters | | | | 148,748 | | | | | 0 | | | | | 148,748 | | | | | | 148,743 | | | | | 0 | | | | | 148,743 | | | ||||||
Mitchell Creem | | | | 144,375 | | | | | 0 | | | | | 144,375 | | | | | | 144,375 | | | | | 0 | | | | | 144,375 | | | ||||||
Michael Reed | | | | 144,375 | | | | | 0 | | | | | 144,375 | | | | | | 144,375 | | | | | 0 | | | | | 144,375 | | | ||||||
Cheryl Grenas | | | | 131,250 | | | | | 0 | | | | | 131,250 | | | | | | 131,250 | | | | | 0 | | | | | 131,250 | | |
Plan category | | | Number of securities to be issued upon exercise of outstanding options, warrants and rights | | | Weighted-average exercise price of outstanding options, warrants and rights | | | Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) | | | Notes | | |||||||||
| | | (a) | | | (b) | | | (c) | | | | | |||||||||
Equity compensation plans approved by security holders | | | | | 5,147,770 | | | | | $ | 2.32 | | | | | | 1,352.240 | | | | 6,500,010 Original reserve when plan approved by security holders | |
Equity compensation plans not approved by security holders | | | | | | | | | | | | | | | | | | | | | | |
Total | | | | | 5,147,770 | | | | | $ | 2.32 | | | | | | 1,352,240 | | | | | |
| | | Authorized | | | Issued and Outstanding | | | Reserved for Future Issuance Pursuant to Outstanding Stock Options | | | Reserved for Future Issuance Pursuant to Outstanding Warrants | | | Reserved for Future Issuance Pursuant to Outstanding RSUs | | | Reserved for Future Issuance Pursuant to 2023 Equity Plan | | ||||||||||||||||||
Pre-Reverse Stock Split | | | | | 950,000,000 | | | | | | 745,426,859 | | | | | | 4,137,149 | | | | | | 97,780,228 | | | | | | 194,720 | | | | | | 15,824,784 | | |
Post-Reverse Stock Split 1 for 15 | | | | | 950,000,000 | | | | | | 49,719,375 | | | | | | 275,810 | | | | | | 6,518,682 | | | | | | 12,980 | | | | | | 1,054,986 | | |
| | | Authorized | | | Issued and Outstanding | | | Reserved for Future Issuance Pursuant to Outstanding Stock Options | | | Reserved for Future Issuance Pursuant to Outstanding Warrants | | | Reserved for Future Issuance Pursuant to Outstanding RSUs | | | Reserved for Future Issuance Pursuant to 2023 Equity Plan | | ||||||||||||||||||
Pre-Reverse Stock Split | | | | | 950,000,000 | | | | | | 49,700,000 | | | | | | 275,810 | | | | | | 6,518,682 | | | | | | 12,980 | | | | | | 1,054,986 | | |
Post-Reverse Stock Split 1 for 2 | | | | | 950,000,000 | | | | | | 24,850,000 | | | | | | 137,905 | | | | | | 3,259,341 | | | | | | 6,490 | | | | | | 527,493 | | |
Post-Reverse Stock Split 1 for 5 | | | | | 950,000,000 | | | | | | 9,940,000 | | | | | | 55,162 | | | | | | 1,303,736 | | | | | | 2,596 | | | | | | 210,997 | | |
Post-Reverse Stock Split 1 for 10 | | | | | 950,000,000 | | | | | | 4,970,000 | | | | | | 27,581 | | | | | | 651,868 | | | | | | 1,298 | | | | | | 105,499 | | |
Post-Reverse Stock Split 1 for 16 | | | | | 950,000,000 | | | | | | 3,106,250 | | | | | | 17,238 | | | | | | 407,417 | | | | | | 811 | | | | | | 65,936 | | |
| | Year Ended December 31, | | | Year Ended December 31, | | ||||||||||||||||||||
| | 2022 | | 2021 | | | 2023 | | 2022 | | ||||||||||||||||
Audit Fees | | | $ | 1,424,460 | | | | $ | 646,325 | | | | | $ | 1,001,389 | | | | $ | 1,424,460 | | | ||||
Audit Related Fees | | | | 29,355 | | | | | 25,750 | | | | | | 0 | | | | | 29,355 | | | ||||
Tax Fees | | | | 0 | | | | | 0 | | | | | | 0 | | | | | 0 | | | ||||
Other Fees | | | | 0 | | | | | 0 | | | | | | 0 | | | | | 0 | | | ||||
Total | | | $ | 1,453,815 | | | | $ | 672,075 | | | | | $ | 1,001,389 | | | | $ | 1,453,815 | | |
Name | | | Age | | | Position(s) | |
Tomas T. Vo, MD, MBA | | | 51 | | | Chief Executive Officer and Chairman of the Board | |
Warren Hosseinion, MD | | | 52 | | | President and Director | |
Joshua DeTillio | | | 48 | | | Chief Operating Officers (as of September 5, 2023) | |
Jon Bates, MBA, CPA | | | 54 | | | Chief Financial Officer | |
Pamela Montgomery, ESQ., LLM, MSN, BSN, RN | | | 67 | | | Chief Legal Officer — Healthcare | |
Elisa Luqman, ESQ., MBA | | | 59 | | | Chief Legal Officer — SEC | |
Michael Chang, MD | | | 53 | | | Chief Medical Officer | |
Name of Beneficial Owner | | | Amount and Nature of Beneficial Ownership | | | Percent of Class | | ||||||
Tom Vo, Chairman and CEO(1) | | | | | 17,988,185 | | | | | | 36.20% | | |
Warren Hosseinion, President and Director(2) | | | | | 115,217 | | | | | | * | | |
Mitchell Creem, Director(3) | | | | | 26,258 | | | | | | * | | |
Cheryl Y. Grenas, Director(4) | | | | | 667 | | | | | | * | | |
Michael L. Reed, Director(5) | | | | | 667 | | | | | | * | | |
Scott J. Saunders, Director | | | | | — | | | | | | * | | |
Kelvin Spears, Director | | | | | 318,828 | | | | | | * | | |
Joshua DeTillio, Chief Operating Officer | | | | | 9,333 | | | | | | * | | |
Jon C. Bates, Chief Financial Officer(6) | | | | | 12,568 | | | | | | * | | |
Michael Chang, Chief Medical Officer(7) | | | | | 800,568 | | | | | | 1.61% | | |
Pamela Montgomery, Chief Legal Officer – Healthcare(8) | | | | | 4,100 | | | | | | * | | |
Elisa Luqman. Chief Legal Officer – SEC(9) | | | | | 45,332 | | | | | | * | | |
Executive Officers and Directors as a Group | | | | | 19,321,722 | | | | | | 38.52% | | |
| | | Option Awards | | | Stock Awards | | ||||||||||||||||||||||||||||||||||||||||||
Name | | | Number of Securities Underlying Unexercised Options(#): Exercisable | | | Number of Securities Underlying Unexercised Options (#): Unexerciseable | | | Option Exercise Price | | | Option Expiration Date | | | Number of Shares or Units of Stock That Have Not Vested (#) | | | Market Value of Shares or Units of Stock That Have Not Vested ($) | | | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested ($) | | | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($) | | ||||||||||||||||||||||||
Thomas T. Vo | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Warren Hosseinion | | | | | 1,659,779 | | | | | | 1,659,779 | | | | | | (1) | | | | | | (1) | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Jon C. Bates | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Michael Bowen | | | | | 200,000 | | | | | | 200,000 | | | | | $ | 2.75 | | | | | | 9/9/2031 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Elisa Luqman | | | | | 667,106 | | | | | | 667,106 | | | | | | (2) | | | | | | (2) | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Pamela Montgomery | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
| Thomas T. Vo | | | Chief Executive Officer (former CEO at Nutex Holdco); | |
| Warren Hosseinion | | | President (former CEO at Clinigence); | |
| Michael Bowen | | | Chief Financial Officer (former CFO at Clinigence); | |
| Elisa Luqman | | | Chief Legal Officer — SEC (former Chief Legal Officer at Clinigence); and | |
| Pam Montgomery | | | Chief Legal Officer — Healthcare (former Chief Legal Officer at Nutex Holdco). | |
Current Officers Name & Principal Position | | | Year | | | Salary ($) | | | Bonus ($) | | | Stock(1) ($) | | | Option Awards(2) ($) | | | Non-equity Incentive Plan Compensation ($) | | | Change in pension value and Nonqualified Deferred Compensation Earnings ($) | | | All Other Compensation ($) | | | Total ($) | | |||||||||||||||||||||||||||
Thomas T. Vo, MD, MBA, Chief Executive Officer(4) | | | | | 2022 | | | | | | 931,841 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 6,384(8) | | | | | | 938,225 | | |
| | | 2021 | | | | | | 251,310 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 6,354 | | | | | | 257,664 | | | ||
| | | 2020 | | | | | | 151,310 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 7,536 | | | | | | 158,846 | | | ||
Warren Hosseinion MD, President(5) | | | | | 2022 | | | | | | 686,350 | | | | | | 0 | | | | | | 0 | | | | | | 1,960,228 | | | | | | 0 | | | | | | 0 | | | | | | 25,500(8) | | | | | | 2,672,078 | | |
| | | 2021 | | | | | | 342,805 | | | | | | 150,000 | | | | | | 0 | | | | | | 964,602 | | | | | | 0 | | | | | | 0 | | | | | | 375,263(3) | | | | | | 1,307,407 | | | ||
| | | 2020 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 338,638 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 338,638 | | | ||
Jon Bates, MBA, CPA Chief Financial Officer(6) | | | | | 2022 | | | | | | 150,000 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 2,912(8) | | | | | | 152,912 | | |
| | | 2021 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | ||
| | | 2020 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | ||
Michael Bowen(7) | | | | | 2022 | | | | | | 230,100 | | | | | | 0 | | | | | | 0 | | | | | | 455,984 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 642,600 | | |
| | | 2021 | | | | | | 167,509 | | | | | | 50,000 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 217,509 | | | ||
| | | 2020 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | ||
Pamela Montgomery, ESQ., | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
LL.M, MSN, BSN, RN Chief Legal Officer – Healthcare | | | | | 2022 | | | | | | 247,596 | | | | | | 12,500 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 15,259(8) | | | | | | 275,355 | | |
| | | 2021 | | | | | | 143,872 | | | | | | 86,402 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 14,034 | | | | | | 244,308 | | | ||
| | | 2020 | | | | | | 143,872 | | | | | | 62,018 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 8,786 | | | | | | 214,676 | | | ||
Elisa Luqman, ESQ., MBA Chief Legal Officer – SEC | | | | | 2022 | | | | | | 251,334 | | | | | | 0 | | | | | | 0 | | | | | | 341,988 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 593,322 | | |
| | | 2021 | | | | | | 157,600 | | | | | | 125,000 | | | | | | 2,415 | | | | | | 643,068 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 928,083 | | | ||
| | | 2020 | | | | | | 133,225 | | | | | | 0 | | | | | | 0 | | | | | | 217,328 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 350,553 | | |
Name and Principal Position | | | Year | | | Salary ($) | | | Stock ($) | | | Option Awards ($) | | | All Other Compensation ($) | | | Total ($) | | ||||||||||||||||||
Thomas T. Vo | | | | | 2023 | | | | | | 992,077 | | | | | | 0 | | | | | | 0 | | | | | | 13,634(5) | | | | | | 1,005,711 | | |
Chief Executive Officer(2) | | | | | 2022 | | | | | | 931,841 | | | | | | 0 | | | | | | 0 | | | | | | 6,384(5) | | | | | | 938,225 | | |
Warren Hosseinion | | | | | 2023 | | | | | | 710,180 | | | | | | 0 | | | | | | 0 | | | | | | 24,207(5) | | | | | | 734,387 | | |
President(3) | | | | | 2022 | | | | | | 686,350 | | | | | | 0 | | | | | | 1,960,228 | | | | | | 25,500(5) | | | | | | 2,672,078 | | |
Jon Bates | | | | | 2023 | | | | | | 361,582 | | | | | | 70,200(6) | | | | | | 0 | | | | | | 21,931(5) | | | | | | 453,713 | | |
Chief Financial Officer(4) | | | | | 2022 | | | | | | 150,000 | | | | | | 0 | | | | | | 0 | | | | | | 2,912(5) | | | | | | 152,912 | | |
| | | Option Awards | | | Stock Awards | | ||||||||||||||||||||||||||||||||||||||||||
Name | | | Number of Securities Underlying Unexercised Options(#): Exercisable | | | Number of Securities Underlying Unexercised Options (#): Unexerciseable | | | Option Exercise Price ($) | | | Option Expiration Date | | | Number of Shares or Units of Stock That Have Not Vested (#) | | | Market Value of Shares or Units of Stock That Have Not Vested ($) | | | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested ($) | | | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($) | | ||||||||||||||||||||||||
Warren Hosseinion | | | | | 100,000 | | | | | | 0 | | | | | | 1.50 | | | | | | 1/27/2030 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
| | | | | 100,000 | | | | | | 0 | | | | | | 1.50 | | | | | | 1/28/2031 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
| | | | | 600,000 | | | | | | 0 | | | | | | 1.61 | | | | | | 5/11/2027 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
| | | | | 859,779 | | | | | | 0 | | | | | | 2.75 | | | | | | 9/9/2031 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Jon C. Bates | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 49,500 | | | | | | 8,910 | | |
Name | | | Number of Shares Acquired on Exercise (#) | | | Value Realized on Exercise ($) | | | Number of Shares Acquired on Vesting (#) | | | Value Realized on Vesting ($)(1) | | ||||||||||||
Thomas T. Vo | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Warren Hosseinion | | | | | — | | | | | | — | | | | | | 859,779 | | | | | | 1,960,228 | | |
Jon C. Bates | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Michael Bowen | | | | | — | | | | | | — | | | | | | 200,000 | | | | | | 455,985 | | |
Elisa Luqman | | | | | — | | | | | | — | | | | | | 150,000 | | | | | | 341,988 | | |
Pamela Montgomery | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Name | | | Number of Shares Acquired on Exercise (#) | | | Value Realized on Exercise ($) | | | Number of Shares Acquired on Vesting (#) | | | Value Realized on Vesting ($)(1) | | ||||||||||||
Jon C. Bates | | | | | — | | | | | | — | | | | | | 99,000 | | | | | $ | 14,850 | | |
Name | | Salary and Other Cash Payments ($)(1) | | Bonus ($)(2) | | Vesting of Stock Options ($)(3) | | Vesting of RSUs ($)(4) | | Health and Dental Benefits ($)(5) | | Total ($) | | | Salary and Other Cash Payments ($)(1) | | Bonus ($)(2) | | Vesting of Stock Options ($)(3) | | Vesting of RSUs ($) | | Health and Dental Benefits ($)(4) | | Total ($) | | ||||||||||||||||||||||||||||||||||||||||||||||||
Thomas T. Vo | | | | 3,000,000 | | | | | 0 | | | | | 0 | | | | | 0 | | | | | 0 | | | | | 3,000,000 | | | | | | 3,000,000 | | | | | 0 | | | | | 0 | | | | | 0 | | | | | 0 | | | | | 3,013,634 | | | ||||||||||||
Warren Hosseinion | | | | 1,500,000 | | | | | 0 | | | | | 0 | | | | | 0 | | | | | 51,000 | | | | | 1,551,000 | | | | | | 1,500,000 | | | | | 0 | | | | | 0 | | | | | 0 | | | | | 24,207 | | | | | 1,524,207 | | | ||||||||||||
Jon C. Bates | | | | 300,000 | | | | | 120,000 | | | | | 0 | | | | | 0 | | | | | 6,000 | | | | | 426,000 | | | | | | 300,000 | | | | | 0 | | | | | 0 | | | | | 8,910 | | | | | 14,463 | | | | | 323,373 | | | ||||||||||||
Michael Bowen | | | | 0 | | | | | 0 | | | | | 0 | | | | | 0 | | | | | 0 | | | | | 0 | | | |||||||||||||||||||||||||||||||||||||||||||
Elisa Luqman | | | | 250,000 | | | | | 0 | | | | | 0 | | | | | 0 | | | | | 0 | | | | | 250,000 | | | |||||||||||||||||||||||||||||||||||||||||||
Pamela Montgomery | | | | 250,000 | | | | | 0 | | | | | 0 | | | | | 0 | | | | | 30,600 | | | | | 280,600 | | |
(a) | | | (b) | | | (c) | | | (d) | | | (e) | | | (f) | | | (g) | | | Value of Initial Fixed $100 Investment Based On: | | | (j) | | | (k) | | |||||||||||||||||||||||||||||||||
| (h) | | | (i) | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Year | | | Summary Compensation Table Total for First PEO ($)(1) | | | Summary Compensation Table Total for Second PEO ($)(1) | | | Compensation Actually Paid to First PEO ($)(2) | | | Compensation Actually Paid to Second PEO ($)(2) | | | *Average Summary Compensation Table Total for Non-PEO Named Executive Officers ($)(3) | | | *Average Compensation Actually Paid to Non-PEO Named Executive Officers ($)(4) | | | Total Shareholder Return ($)(5) | | | Peer Group Total Shareholder Return ($)(6) | | | Net Income (Loss) ($)(7) | | | Adjusted EBITDA ($)(8) | | ||||||||||||||||||||||||||||||
2022 | | | | | 938,225 | | | | | | 2,672,078 | | | | | | 938,225 | | | | | | 2,192,404 | | | | | | 416,047 | | | | | | 319,133 | | | | | | (4.50) | | | | | | (0.49) | | | | | | (424,780,446) | | | | | | 12,547,923 | | |
2022 ($) | | ||||||||||||||||||||||||
Year | | | Reported summary Compensation Table Total for Second PEO | | | Reported Value of Equity Awards for Second PEO(a) | | | Equity Award Adjustments(b) | | | Compensation Actually paid to Second PEO | | ||||||||||||
2022 | | | | | 2,672,078 | | | | | | 1,960,228 | | | | | | (479,674) | | | | | | 2,192,404 | | |
Year | | | Summary Compensation Table Total for First PEO(1) | | | Summary Compensation Table Total for Second PEO(1) | | | Compensation Actually Paid to First PEO(1)(2) | | | Compensation Actually Paid to Second PEO(1)(2) | | | Average Summary Compensation Table Total for Non-PEO NEOs(1) | | | Average Compensation Actually Paid to Non-PEO NEOs(1)(2) | | | Value of Initial Fixed $100 Investment Based on TSR | | | Net Income (Loss) (in thousands) | | ||||||||||||||||||||||||
2023 | | | | | — | | | | | $ | 1,005,711 | | | | | | — | | | | | $ | 1,005,711 | | | | | $ | 594,050 | | | | | $ | 558,950 | | | | | $ | (2,715) | | | | | $ | (45,786) | | |
2022 | | | | $ | 2,672,078 | | | | | $ | 931,841 | | | | | $ | 711,850 | | | | | $ | 931,841 | | | | | $ | 419,418 | | | | | $ | 191,506 | | | | | $ | (450) | | | | | $ | (424,780) | | |
2021 | | | | $ | 1,832,670 | | | | | | — | | | | | $ | 492,805 | | | | | | — | | | | | $ | 572,976 | | | | | $ | 250,055 | | | | | $ | N/A | | | | | $ | (N/A) | | |
| Average Reported summary Compensation Table Total for Non-PEO Named Executive Officers | | | Average Reported Value of Equity Awards for Non-PEO Named Executive Officers(c) | | | Equity Award Adjustments for Non-PEO Named Executive Officers(d) | | | Compensation Actually for Non-PEO Named Executive Officers | |
| 416,047 | | | 398,987 | | | (96,914) | | | 319,133 | |
| | | 2023 | | | 2022 | | ||||||
FIRST PEO SUMMARY COMPENSATION TABLE TOTAL | | | | $ | 1,005,711 | | | | | $ | 2,672,078 | | |
Add (Subtract): | | | | | | | | | | | | | |
Fair value of equity awards granted during the year from the Summary Compensation Table | | | | $ | — | | | | | | 1,960,228 | | |
Fair value at year end of equity awards granted during the year | | | | | — | | | | | | — | | |
Change in fair value of equity awards granted in prior years that were unvested as of the end of the year | | | | | — | | | | | | — | | |
Change in fair value of equity awards granted in current year that vested during the year | | | | | — | | | | | | — | | |
Change in fair value of equity awards granted in prior years that vested during the year | | | | | — | | | | | | — | | |
Equity awards granted in prior years that were forfeited during the year | | | | | — | | | | | | — | | |
Tax Gross up(a) | | | | $ | — | | | | | | — | | |
COMPENSATION ACTUALLY PAID TOTAL | | | | $ | 1,005,711 | | | | | $ | 711,850 | | |
| | | 2023 | | | 2022 | | ||||||
NON-PEO NEOS SUMMARY COMPENSATION TABLE TOTAL | | | | $ | 594,050 | | | | | $ | 419,418 | | |
Add (Subtract): | | | | | | | | | | | | | |
Fair value of equity awards granted during the year from the Summary Compensation Table | | | | $ | 35,100 | | | | | $ | 227,912 | | |
Fair value at year end of equity awards granted during the year | | | | | | | | | | | | | |
Change in fair value of equity awards granted in prior years that were unvested as of the end of the year | | | | | — | | | | | | — | | |
Change in fair value of equity awards granted in current year that vested during the year | | | | | — | | | | | | — | | |
Change in fair value of equity awards granted in prior years that vested during the year | | | | | — | | | | | | — | | |
Equity awards granted in prior years that were forfeited during the year | | | | | — | | | | | | — | | |
Dividends or other earnings paid on equity awards during the year | | | | | — | | | | | | — | | |
Total Equity Award Related Adjustments | | | | $ | — | | | | | $ | 227,912 | | |
COMPENSATION ACTUALLY PAID TOTAL | | | | $ | 558,950 | | | | | $ | 191,506 | | |
Plan category | | Number of securities to be issued upon exercise of outstanding options, warrants and rights | | Weighted- average exercise price of outstanding options, warrants and rights | | Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) | | | Number of securities to be issued upon exercise of outstanding options, warrants and rights | | Weighted- average exercise price of outstanding options, warrants and rights | | Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) | | ||||||||||||||||||||||||
| | (a) | | (b) | | (c) | | | (a) | | (b) | | (c) | | ||||||||||||||||||||||||
Equity compensation plans approved by security holders | | | | 5,147,770 | | | | $ | 2.32 | | | | | 1,352.240 | | | | | | 5,147,770 | | | | $ | 2.32 | | | | | 1,352,240 | | | ||||||
Equity compensation plans not approved by security holders | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||
Total | | | | 5,147,770 | | | | $ | 2.32 | | | | | 1,352,240 | | | | | | 5,147,770 | | | | $ | 2.32 | | | | | 1,352,240 | | |
Name of Beneficial Owner | | | Amount and Nature of Beneficial Ownership | | | Percent of Class | | ||||||
Tom Vo, Chairman and CEO(1) | | | | | 267,322,776 | | | | | | 40.76% | | |
Premier Macy Management Holdings, LLC(2) | | | | | 41,964,832 | | | | | | 6.40% | | |
Dr. Danniel Stites(3) | | | | | 6,355,402 | | | | | | *% | | |
Warren Hosseinion, President and Director(4) | | | | | 1,930,047 | | | | | | * | | |
Mitchell Creem, Director(5) | | | | | 343,866 | | | | | | * | | |
Cheryl Y. Grenas, Director | | | | | — | | | | | | * | | |
Michael L. Reed, Director | | | | | — | | | | | | * | | |
John J. Waters, Director(6) | | | | | 508,320 | | | | | | * | | |
Jon C. Bates, Chief Financial Officer(7) | | | | | 168,515 | | | | | | * | | |
Elisa Luqman, Chief Legal Officer (SEC) and Secretary(8) | | | | | 679,976 | | | | | | * | | |
Pamela W. Montgomery, Chief Legal Officer (Healthcare)(9) | | | | | 49,505 | | | | | | * | | |
Executive Officers and Directors as a Group | | | | | 319,323,239 | | | | | | 48.68% | | |